Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
60 hedge funds and large institutions have $131M invested in Provention Bio, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 11 closing their positions.
211% more capital invested
Capital invested by funds: $42.2M → $131M (+$88.9M)
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
109% more call options, than puts
Call options by funds: $3.75M | Put options by funds: $1.79M
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
25% more funds holding
Funds holding: 48 → 60 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$20.1M |
| 2 |
BlackRock
New York
|
+$1.55M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.41M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.36M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.95M |
| 2 |
SCM
Segantii Capital Management
Hong Kong
|
-$4.13M |
| 3 |
Morgan Stanley
New York
|
-$1.76M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.7M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.37M |
PRVB Hedge Fund Activity: Q4 2019 in Review
60 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2019, worth a combined $131M — up 211% from $42.2M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PRVB positions and 11 closed out — a net gain of 13 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $20.1M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.95M sold.
- 60 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2019, up from 48 in Q3 2019.
- Funds reported $131M of Provention Bio, Inc. Common Stock stock for Q4 2019, up 211% quarter-over-quarter.
- 24 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2019 and 11 closed out, a net change of +13 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q4 2019 was Perceptive Advisors, an estimated $20.1M added.
- The largest Provention Bio, Inc. Common Stock seller in Q4 2019 was Deerfield Management, an estimated $4.95M sold.
Based on aggregated 13F filings for Q4 2019.